<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0">
<channel>
<title><![CDATA[EC21 Product Catalogs - anticancer]]></title>
<link><![CDATA[https://www.ec21.com/ec-market/anticancer--2143/1/anticancer.html]]></link><item>
<title><![CDATA[Embomycin B]]></title><link><![CDATA[https://azzzzz11111.en.ec21.com/Embomycin_B--11871931_11871979.html]]></link><description><![CDATA[the same mechanism of action as paclitaxel to inhibit tumor cell growth, and exhibits potent anticancer activity against both multidrug-resistant tumor cells and paclitaxel-resistant tumor cells.
]]></description><pubDate><![CDATA[20231130]]></pubDate></item>
<item>
<title><![CDATA[Acalabrutinib]]></title><link><![CDATA[https://1040801346.en.ec21.com/Acalabrutinib--11848901_11848910.html]]></link><description><![CDATA[CP-196 is an experimental anticancer drug that is a selective Bruton tyrosine kinase (BTK) inhibitor. This kinase transmits signals from the B-cell receptor (BCR), so any inherited BTK mutation will ]]></description><pubDate><![CDATA[20230928]]></pubDate></item>

</channel>
</rss>